- Trials with a EudraCT protocol (76)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
76 result(s) found for: Weaning.
Displaying page 1 of 4.
EudraCT Number: 2015-002114-80 | Sponsor Protocol Number: TIP-15-01 | Start Date*: 2017-03-14 | ||||||||||||||||
Sponsor Name:AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI | ||||||||||||||||||
Full Title: Efficacy and safety of dexmedetomidine during weaning from analgesia and sedation in Pediatric Intensive Care Unit. A multicenter, double-blind, randomized controlled trial. | ||||||||||||||||||
Medical condition: analgesia and sedation | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-003612-30 | Sponsor Protocol Number: 0904HELIOX | Start Date*: 2005-11-23 |
Sponsor Name:Barts and the London NHS Trust | ||
Full Title: A comparison of Helium-oxygen mixture (Heliox) with an oxygen-air mixture in reducing the work of breathing during weaning from mechanical ventilation. | ||
Medical condition: Patients admitted to the intensive care unit who are in the recovery phase of their illness and are weaning from mechanical ventilation. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-004319-29 | Sponsor Protocol Number: P170914J | Start Date*: 2021-10-04 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: " LEVOSIMENDAN to facilitate weaning from ECMO in severe cardiogenic shock patients | |||||||||||||
Medical condition: Adult patients with acute cardiogenic shock refractory to conventional therapy placed on VA-ECMO support and for whom withdrawal from ECMO is possible. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002078-30 | Sponsor Protocol Number: REDNES06052013 | Start Date*: 2013-08-08 |
Sponsor Name:Onze-Lieve-Vrouw Ziekenhuis | ||
Full Title: Acceleromyography and diaphragm electromyographic activity during neostigmine or sugammadex enhanced recovery from moderate residual neuromuscular blockade after rocuronium 0.6 mg kg-1: a double bl... | ||
Medical condition: We will compare usual care (neostigmine) with sugammadex for reversal of a moderate rocuronium-induced neuromuscular blockade and assess the effect on diaphragmatic EMG activity of sugammadex versu... | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-001276-20 | Sponsor Protocol Number: USA107212 | Start Date*: 2006-12-05 |
Sponsor Name:GlaxoSmithKline GmbH & Co. KG | ||
Full Title: A randomized, open-label, multicenter, parallel-group study to compare the efficacy, safety and resource utilization of a remifentanil/propofol analgosedation regimen versus a sufentanyl/propofol a... | ||
Medical condition: Ventilated patients under intensive medical care with an expected duration of analgosedation of up to 7 days | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-001623-13 | Sponsor Protocol Number: T3inj-02/Thy-Support | Start Date*: 2020-05-20 | |||||||||||
Sponsor Name:Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. | |||||||||||||
Full Title: Triiodothyronine for the treatment of critically ill patients with COVID-19 infection (Thy-Support Study) | |||||||||||||
Medical condition: ICU patients diagnosed with pulmonary infection due to COVID-19 and require mechanical respiratory support or ECMO | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002509-22 | Sponsor Protocol Number: ID2687 | Start Date*: 2019-11-21 | |||||||||||
Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE | |||||||||||||
Full Title: Impact of totally transdermal sedation in the weaning from remifentanil infusion among critically ill patients undergoing mechanical ventilation: a pilot randomized-controlled Study | |||||||||||||
Medical condition: Invasive mechanical ventilation is a lifesaving intervention among critically ill patients. However, prolonged ventilation is associated with increased morbidity and mortality. Optimal processes fo... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-010640-34 | Sponsor Protocol Number: THYTOTRA | Start Date*: 2009-08-13 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA POLICLINICO DI MODENA | |||||||||||||
Full Title: INDUCTION OF DONOR-SPECIFIC TOLERANCE IN PATIENTS WITH LIVER TRANSPLANTATION WITH RECIPIENT PRE-TREATMENT WITH THYMOGLOBULINE AND MINIMAL POST-TRANSPLANT IMMUNOSUPPRESSION. | |||||||||||||
Medical condition: Adult recipients of first liver transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-010366-28 | Sponsor Protocol Number: 69/09 | Start Date*: 2009-06-13 | |||||||||||||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||||||||||||
Full Title: Effects of different doses of remifentanil in patients ventilated in Pressure Support Ventilation (PSV) vs Neurally Adjusted Ventilatory Assist (NAVA) | |||||||||||||||||||||||
Medical condition: Acute Respiratory Failure (ARF) or with a difficult weaning in patients ventilated | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004851-12 | Sponsor Protocol Number: 06/Q0504/33 | Start Date*: 2008-01-03 | |||||||||||
Sponsor Name:Whittington Hospital NHS Trust | |||||||||||||
Full Title: Prospective randomised cross over comparison on the physiological response to non-invasive ventilation using either Air O2 or Heliox21 | |||||||||||||
Medical condition: Respiratory failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-009599-11 | Sponsor Protocol Number: 08/0339 | Start Date*: 2011-02-15 |
Sponsor Name:Joint UCLH/UCL/Royal Free Biomedical Research Unit | ||
Full Title: Prospective randomised cross over comparison on the physiological response to non-invasive ventilation using either Air O2 or Heliox21 | ||
Medical condition: Respiratory failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2013-001926-25 | Sponsor Protocol Number: B300201316844 | Start Date*: 2013-09-23 |
Sponsor Name:Universitair Ziekenhuis Antwerpen | ||
Full Title: Sugammadex and the diaphragm: recovery of diaphragmatic function and neuromuscular blockade | ||
Medical condition: Residual neuromuscular blockade and diphragm fatigue | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-002907-15 | Sponsor Protocol Number: AC-051-350 | Start Date*: 2007-03-21 | |||||||||||
Sponsor Name:Actelion Pharmaceuticals Ltd | |||||||||||||
Full Title: Multicenter, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of tezosentan in patients with pre-operative pulmonary hypertension, ... | |||||||||||||
Medical condition: Cardiac Surgery, Separation from cardiopulmonary bypass | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SE (Completed) FR (Completed) AT (Completed) SK (Completed) IT (Completed) CZ (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001393-16 | Sponsor Protocol Number: SHP607-202 | Start Date*: 2019-06-21 | |||||||||||
Sponsor Name:Premacure AB | |||||||||||||
Full Title: A Phase 2b, Multicenter, Randomized, Open-label, Controlled, 3-Arm Study to Evaluate the Clinical Efficacy and Safety of SHP607 in Preventing Chronic Lung Disease Through 12 Months Corrected Age Co... | |||||||||||||
Medical condition: Chronic Lung Disease | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IE (Trial now transitioned) SE (Prematurely Ended) FR (Completed) DE (Trial now transitioned) PT (Trial now transitioned) ES (Temporarily Halted) FI (Trial now transitioned) NL (Trial now transitioned) PL (Prematurely Ended) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002142-31 | Sponsor Protocol Number: 547-SSE-301 | Start Date*: 2016-11-16 | |||||||||||
Sponsor Name:Sage Therapeutics | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SAGE-547 INJECTION IN THE TREATMENT OF SUBJECTS WITH SUPER-REFRACTORY STATUS EPILEPTICUS | |||||||||||||
Medical condition: SUPER-REFRACTORY STATUS EPILEPTICUS (SRSE) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) SE (Completed) DK (Completed) ES (Completed) NL (Completed) FI (Completed) HU (Completed) AT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003182-34 | Sponsor Protocol Number: 2018-10 | Start Date*: 2018-10-18 |
Sponsor Name:CHR d'ORLEANS | ||
Full Title: Randomized, double-blind, controlled clinical trial for comparison of continuous phenylephrine versus norepinephrine infusion for maintenance of hemodynamic stability during cesarean section under... | ||
Medical condition: hypotension during caesarean section under spinal anesthesia | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-004082-41 | Sponsor Protocol Number: DELIcu | Start Date*: 2013-03-06 | |||||||||||
Sponsor Name:Dekan of Faculty of Medicine of Goethe-University Frankfurt | |||||||||||||
Full Title: Monocenter, double blind, randomised, placebo controlled study t evaluate Physostigmin for the Treatment of delirium in perioperative intensive care medicine | |||||||||||||
Medical condition: patients with delirium in perioperative intensive care medicine | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003663-35 | Sponsor Protocol Number: PBF-680CT-05 | Start Date*: 2018-06-13 | |||||||||||
Sponsor Name:Palobiofarma S.L | |||||||||||||
Full Title: A phase II, double-blind, randomized, parallel-group, placebocontrolled multi-center study to investigate the effect of the adenosine A1 receptor antagonist PBF-680 on forced expiratory volume in 1... | |||||||||||||
Medical condition: patients with mild-to-moderate persistent atopic asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001822-81 | Sponsor Protocol Number: TJT1106 | Start Date*: 2011-09-06 | ||||||||||||||||
Sponsor Name:CHU-Ulg | ||||||||||||||||||
Full Title: Infusion of third-party mesenchymal stem cells after renal or liver transplantation: a phase I-II, open-label, clinical study. | ||||||||||||||||||
Medical condition: Liver failure: end-stage liver diseases, including cirrhosis, primary liver cancer, fulminant hepatic failure and numerous other metabolic or congenital hepatic diseases. Kidney failure: end-st... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003050-41 | Sponsor Protocol Number: HJE-PHARMA-001 | Start Date*: 2015-11-10 | |||||||||||
Sponsor Name:Rigshospitalet | |||||||||||||
Full Title: Efficacy of GLP-1 agonists and restrictive vs. liberal FiO2 in patients undergoing coronary artery bypass grafting or aortic valve replacement – a 2-by-2 factorial designed, randomized clinical study | |||||||||||||
Medical condition: We investigate the efficacy of commercially available GLP-1 analog for reducing organ damage in patients undergoing heart surgery (i.e. coronary artery bypass grafting and/or aortic valve replaceme... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
